FOR IMMEDIATE RELEASE
STEM CELLS® AND INVITROGEN PRESENT THE 2nd ANNUAL STEM CELLS® YOUNG INVESTIGATOR AWARD
Awardee named at International Society for Stem Cell Research Meeting
Cairns, Australia, June 15, 2007 – The senior editors of the journal STEM CELLS® today announced Noatsugu Haraguchi, MD, PhD, from Kyushu University in Japan, as the winner of the 2nd Annual STEM CELLS® Young Investigator Award, sponsored by Invitrogen. The $10,000 award is given to a scientist age 40 or younger who is the principal author of the qualifying STEM CELLS® paper from the past year judged to be most important by the editorial panel.
The journal published Dr. Haraguchi’s landmark paper, “Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System,” in their March 2006 issue. The paper is the first known report demonstrating the existence of cancer side population (SP) cells in gastrointestinal cancers. The article is available online at http://stemcells.alphamedpress.org/cgi/content/full/24/3/506.
“Members of our editorial board reviewed many outstanding manuscripts and Dr. Haraguchi’s groundbreaking paper was most deserving of this recognition,” said Dr. Curt I. Civin, Editor-in-Chief. “We are grateful for Invitrogen’s support which enables the journal to further stimulate the field in this way.”
The second annual award will be presented June 20th at 10:45am, at Stem Cells booth #69, at the 5th Annual ISSCR, 2007, in Cairns, Australia. This is the second consecutive year Invitrogen Corporation is supporting the Young Investigator Award with a $10,000 unrestricted education grant.
“Invitrogen is committed to empowering scientists in all areas of the life sciences, especially those programs that recognize the vital contributions of today’s young stem cell researchers,” said Dr. Mahendra Rao, Invitrogen’s Vice President, Research, Stem Cells and Regenerative Medicine. “We are pleased to be honoring the exceptional work of Dr. Haraguchi and to be sponsoring this award with STEM CELLS®, one of the field’s most outstanding journals."
For more information, visit http://stemcells.alphamedpress.org.
About Invitrogen Corporation
Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support
academic and government research institutions and pharmaceutical and biotech
companies worldwide in their efforts to improve the human condition. The company
provides essential life science technologies for disease research, drug discovery,
and commercial bioproduction. Invitrogen's own research and development efforts
are focused on breakthrough innovation in all major areas of biological discovery
including functional genomics, proteomics, bioinformatics and cell biology --
placing Invitrogen's products in nearly every major laboratory in the world.
Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts
business in more than 70 countries around the world. The company is celebrating
20 years of accelerating scientific discovery. Invitrogen globally employs approximately
4,300 scientists and other professionals and had revenues of more than $1.15
billion in 2006. For more information, visit www.invitrogen.com/stemcell.
About STEM CELLS®
STEM CELLS®, the international journal of cell differentiation
and proliferation, publishes original articles and concise reviews describing
basic laboratory investigations of stem cells and the translation to patient
care. The Journal covers all aspects of stem cells and regenerative medicine.
Currently in its 25th year of publication, STEM CELLS® is the
first journal devoted to this fast-paced field of research. Its current Impact
Factor of 6.094 places it in the top 3% of all high-impact international journals.
Contacts
STEM CELLS:
Media: George Kendall (919) 680-0011 ext. 224, gkendall{at}alphamedpress.com
Invitrogen Corporation:
Media: Eric Endicott, (760) 268-7438, eric.endicott{at}invitrogen.com
Agency: Carolyn Hawley, Porter Novelli Life Sciences (858)
527-3484, chawley{at}pnlifesciences.com